Dr. Andrew Huberman

This is not something to get cavalier with.

This is something only to be done in a clinical context with medical experts there.

And iboga is very interesting.

From what I'm told, I have not participated in an iboga trial.

Iboga allows for or induces a state in which you do not hallucinate at all with eyes open, but the moment you go eyes closed, you get a high-resolution, accurate picture of

of prior events in your life, but you have agency, you have volition inside of those pictures, and you're able to change your behavior and re-sculpt your relationship to those experiences.

Like, wow.

And the state of Kentucky in California recently, excuse me, the state of Kentucky in the United States, thank goodness Kentucky isn't inside of California, that would be civil war.

The state of Kentucky recently took the $40 million settlement from the opioid thing, right?

You've all heard about that, the opioid crisis, and applied that money to iboga trials.

So this stuff is happening.

This stuff is really happening now in the U.S.

In any event, psilocybin...

These two sessions, medically supported two sessions, has been shown to be pretty effective in the treatment of major depression.

Not completely effective.

Sometimes there's adverse outcomes, but far more effective than the other pharmaceutical treatments that it's been compared to.

So that's interesting.

And psilocybin is serotonin.

If you look at the structure of psilocybin, it looks like serotonin.

So what we're talking about is a massive dose of serotonin